Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Long-Acting Amylin Agonist AZD6234 AZD6234 is a novel long-acting selective AMY3R agonist developed by AstraZeneca for SC administration, and is currently in phase 2 testing [114]
R.ParkA
It was originally developed for type 2 diabetes management (Ozempic) but showed such dramatic weight loss effects that the FDA approved a higher-dose formulation for chronic weight management (Wegovy)
doi: 10.1126/science.1092385 13 TalwarDMillerCGGrossmannJSzyrwielLSchweckeTDemichevVet al
10.1111/2049-632x.12077 30 Casares-CrespoL.Calatayud-BaselgaI.Garca-CorzoL.MiraH
US$ 21.21
US$ 21.29
US$ 27.55
US$ 27.36
US$ 26.20
